Ipsen: Ipsen posts an 11.6% increase in turnover in the 1st quarter, confirms its 2025 forecasts

Ipsen reported on Wednesday an increase in its turnover of 11.6% at constant exchange rates in the first quarter, driven by all therapeutic areas and a growing contribution from Iqirvo and Bylvay. The group's turnover amounted to 918.8 million euros for the period from January to the end of March. In February, Ipsen had stated that it expected total sales growth of more than 5% at constant exchange rates and an operating margin from activities of more than 30%. (Written by Elena Smirnova, edited by Kate Entringer) The group's turnover amounted to 918.8 million euros for the period from January to the end of March. In February, Ipsen had stated that it expected total sales growth of more than 5% at constant exchange rates and an operating margin from activities of more than 30%. (Written by Elena Smirnova, edited by Kate Entringer)